Allspring Global Investments Holdings LLC Has $3.05 Million Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Allspring Global Investments Holdings LLC cut its holdings in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 95.6% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 45,460 shares of the medical device company's stock after selling 997,014 shares during the quarter. Allspring Global Investments Holdings LLC's holdings in DexCom were worth $3,048,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Canada Pension Plan Investment Board increased its position in shares of DexCom by 189.1% during the second quarter. Canada Pension Plan Investment Board now owns 665,646 shares of the medical device company's stock worth $75,471,000 after acquiring an additional 435,401 shares during the period. Massachusetts Financial Services Co. MA grew its holdings in shares of DexCom by 16.9% during the second quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company's stock worth $276,538,000 after purchasing an additional 353,019 shares during the last quarter. Bellevue Group AG lifted its holdings in shares of DexCom by 33.5% in the 1st quarter. Bellevue Group AG now owns 1,221,197 shares of the medical device company's stock valued at $169,380,000 after purchasing an additional 306,604 shares during the last quarter. Magnetar Financial LLC acquired a new stake in shares of DexCom in the 2nd quarter valued at about $31,793,000. Finally, Dimensional Fund Advisors LP lifted its stake in DexCom by 41.3% in the second quarter. Dimensional Fund Advisors LP now owns 919,650 shares of the medical device company's stock valued at $104,282,000 after buying an additional 268,802 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Price Performance

Shares of DXCM traded down $0.25 during midday trading on Wednesday, reaching $71.99. The stock had a trading volume of 624,165 shares, compared to its average volume of 3,898,491. The firm's 50 day moving average price is $69.98 and its 200-day moving average price is $96.73. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00. The company has a market capitalization of $28.63 billion, a P/E ratio of 46.61, a P/E/G ratio of 2.26 and a beta of 1.18. The company has a debt-to-equity ratio of 1.00, a current ratio of 2.82 and a quick ratio of 2.48.

Analysts Set New Price Targets

DXCM has been the subject of several recent research reports. Canaccord Genuity Group reaffirmed a "buy" rating and set a $145.00 price target on shares of DexCom in a report on Tuesday, July 23rd. Piper Sandler restated an "overweight" rating and issued a $90.00 price target on shares of DexCom in a research note on Monday, August 26th. Raymond James decreased their price objective on shares of DexCom from $115.00 to $99.00 and set a "strong-buy" rating on the stock in a research report on Friday, October 25th. Stifel Nicolaus raised their target price on shares of DexCom from $90.00 to $100.00 and gave the company a "buy" rating in a report on Friday, August 23rd. Finally, Barclays reduced their price target on shares of DexCom from $138.00 to $113.00 and set an "equal weight" rating on the stock in a report on Monday, July 29th. Six investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $104.59.

Insiders Place Their Bets

In related news, COO Jacob Steven Leach sold 746 shares of the firm's stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the transaction, the chief operating officer now owns 264,915 shares of the company's stock, valued at approximately $18,318,872.25. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, COO Jacob Steven Leach sold 746 shares of the company's stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the sale, the chief operating officer now directly owns 264,915 shares of the company's stock, valued at approximately $18,318,872.25. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Sadie Stern sold 426 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the sale, the executive vice president now directly owns 75,451 shares of the company's stock, valued at $5,217,436.65. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.30% of the stock is owned by company insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.